Cohance Lifesciences Announces Q4 and FY26 Results FY27 to be a growth year

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited), a leading global CDMO (Contract Development and Manufacturing Organization), today announced its audited financial results for the year ended March 31, 2026.

Q4 and FY26 Financial Performance

· FY26 reported revenue from operations at ₹22.68 billion. Gross margins improved 209 basis points. Adjusted EBITDA margins stood at 21% translating to Adjusted EBITDA of ₹4.8 billion. Standalone Adjusted EBITDA margins were at 24.6%.

· Q4 FY26 Revenue from Operations were ₹6.19 billion while gross margins improved to 65.4%. Adjusted EBITDA at ₹1.29 billion with EBITDA margins at 21%.

·  Adjusted EBITDA for the review periods reflects the impact of subsidiary cost consolidation and muted operating leverage at the consolidated level

Mr. Umang Vohra, Executive Chairman and Group CEO, said: “Cohance today has a strong and differentiated niche technology-led global CDMO platform spanning ADCs, nucleic acid chemistries, small molecules, and complex chemistries, with meaningful engagement across global innovator pharma companies. Today, we see Cohance as a strong, fundamentally relevant platform, deepening customer engagement, and pipeline across businesses. Immediate priority over the next few months will be to spend time with our customers, teams and sites. Over the next few years, we focus to expand Cohance’s capabilities and science, the predictability of delivery, backed by strong quality and systems, a talent pool and a pipeline that matters for our partner’s.”

Key Business Highlights of FY26

·        Leadership structure strengthened under Mr. Umang Vohra, bringing an owner-manager mindset, global operating discipline and sharper execution focus

·        Strengthened leadership, improved customer engagement and sharper execution discipline positions Cohance for growth. The Company is transitioning to a steady-state execution model, with focus shifting from capability build to delivery and conversion.

·        Q4 and full year FY26 performance was aligned with previous guidance.

·        Functional depth enhanced across Business Development, Quality, Regulatory, R&D and Operations, with clear accountability across business units.

·        Added one new Phase III lateral programme in small molecules with large Innovator and one programme each in ADCs and oligonucleotides advanced to the Phase III pipeline. With two programmes progressing towards early commercialisation, the total Phase III pipeline now stands at 10 programme across our platform.

·        Pipeline remains steady with consistent RFP inflows 2x across small molecules, ADC and complex chemistries continues to reinforce pipeline strength; ongoing efforts are focused on enhancing win rates in laterals (late stage pipeline).

Outlook

In FY27, growth will return from 2HFY27 onwards. We believe the business is moving towards a bottoming-out phase, with Q1FY27 to be the low point, both on revenue and EBITDA. We expect growth visible from 2HFY27 onwards, supported by execution on existing programmes, customer conversions, reloads and improving utilisation across the platform.